Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03663335 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 418
- Enrollment target
NCT03663335 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 418 participants.
The verdict
NCT03663335, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 418 participants
- Enrollment target
Study Summary
This study was to compare CFZ533 to tacrolimus (TAC) in prevention of organ rejection in kidney transplant.
Interventions
- DRUG Tacrolimus
- DRUG Mycophenolate Mofetil (MMF)
- DRUG Corticosteroids (CS)
- BIOLOGICAL CFZ533 - Cohort 1/Cohort 2
- DRUG Induction therapy: basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2021-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03663335
The ClinicalTrials.gov registry entry for NCT03663335 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tacrolimus is the first listed.
NCT03663335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03663335 about?
NCT03663335 is a clinical study titled "Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients". This study was to compare CFZ533 to tacrolimus (TAC) in prevention of organ rejection in kidney transplant.
What is the current status of trial NCT03663335?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 418 participants. The study started on 2018-11-28. Estimated completion is 2021-10-29.
What interventions are being tested in trial NCT03663335?
The interventions under investigation include: Tacrolimus (DRUG), Mycophenolate Mofetil (MMF) (DRUG), Corticosteroids (CS) (DRUG), CFZ533 - Cohort 1/Cohort 2 (BIOLOGICAL), Induction therapy: basiliximab (DRUG).
Who is sponsoring clinical trial NCT03663335?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.